A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent.
Age ≥ 18 years.
Performance status of 0 or 1.
Histological diagnosis of malignancy.
Cancer relapsing after, or refractory to standard therapy.
Malignancy over-expressing the c Met protein.
Presence of circulating tumor cells (CTCs).
At least one tumor lesion > 2 cm on PET/CT.
Serum albumin > 35 g/L.
Absolute neutrophil count (ANC) > 1.0 x 109/L.
Hemoglobin > 90 g/L (0.9 g/dL).
Platelet count ≥ 75 x 109/L.
Coagulation parameters ≤ 1.5 x ULN.
Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
Creatine Phosphokinase (CPK) ≤ 2.5 x ULN.
Serum creatinine ≤ 1.5 x ULN.
Ability to comply with protocol-specified procedures/evaluations and scheduled visits.
History or clinical evidence of neoplastic central nervous system (CNS) involvement.
Major surgery within 4 weeks of ARGX 111 first dose administration.
Systemic glucocorticoid administration at doses greater than physiological replacement (prednisone 20 mg equivalent) within 3 weeks of ARGX 111 first dose administration.
Cytotoxic chemotherapy within 3 weeks of ARGX 111 first dose administration.
Radiation therapy with curative intent within 3 weeks of ARGX 111 first dose administration.
Biological therapy (monoclonal antibodies) within 4 weeks of ARGX 111 first dose administration.
Biological therapy (other than monoclonal antibodies) within 5 half-lives of ARGX 111 first dose administration.
Unresolved Grade 3 or 4 toxicity from prior therapy, including experimental therapy.
History of recurrent Grade 3 or 4 toxicity from anti c Met therapy.
Uncontrolled diabetes, defined as fasting glycemia > 150 mg/dl).
Active, untreated viral, bacterial, or systemic fungal infection.
Any clinical finding, including psychiatric and behavioral problems, which, in the opinion of the Investigator, precludes the patient from safely participating in the study.
Childbearing potential (unless using an adequate measure of contraception).
Pregnancy or lactation.
History of severe (Grade 3 or 4) hypersensitivity to recombinant proteins.